Zevra Therapeutics (ZVRA) Convertible Debt (2014 - 2020)

Zevra Therapeutics' Convertible Debt history runs 7 years deep, the most recent figure standing at $67.7 million for Q4 2020.

• Quarterly Convertible Debt fell 12.52% year-over-year to $67.7 million in Q4 2020, while the trailing twelve-month figure through Dec 2020 was $67.7 million (down 12.52% YoY) and the FY2020 annual result came in at $67.7 million, down 12.52% from the prior year.
• Convertible Debt was $67.7 million for Q4 2020 at Zevra Therapeutics, down from $77.3 million in the prior quarter.
• Across five years, Convertible Debt topped out at $92.3 million in Q3 2017 and bottomed at $67.7 million in Q4 2020.
• A 5-year average of $84.5 million and a median of $89.4 million in 2017 frame the typical range for Convertible Debt.
• Annual changes were most pronounced in 2016 — Convertible Debt soared 1130.03% — and 2019, when it declined 19.06%.
• Zevra Therapeutics' Convertible Debt stood at $91.2 million in 2016, then decreased by 1.94% to $89.4 million in 2017, then dropped by 12.63% to $78.1 million in 2018, then declined by 0.98% to $77.3 million in 2019, then decreased by 12.52% to $67.7 million in 2020.
• Business Quant data shows ZVRA's Convertible Debt at $67.7 million in Q4 2020, $77.3 million in Q4 2019, and $70.6 million in Q3 2019.